Moderna developing mRNA vaccine for Lyme disease
A Lyme disease vaccine could be on its way soon, according to pharmaceutical company Moderna.
The company has announced two new mRNA vaccines in development that could prevent Lyme disease, marking the "first application of its mRNA technology to bacterial pathogens." The technology was used in creating the COVID-19 vaccine. Moderna also announced vaccine development plans for norovirus and RSV, which have both been spreading rapidly.
"Untreated, Lyme disease can be very serious," emergency physician and George Washington University professor Leana Wen told Axios. "Some people develop debilitating symptoms that really impact their lives." The disease comes from tick bites and can cause fever, chills, joint pain, and rashes, according to the Centers for Disease Control. If left untreated, the symptoms can be more severe including heart palpitations, arthritis, and facial palsy.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There has only been one human Lyme disease vaccine that was ever available on the market and it was pulled in 2002 because "negative press coverage and limited awareness of the benefits of the vaccine decreased consumer demand for the vaccine," according to a 2007 study. However, there are approximately 120,000 reported cases of Lyme reported each year in the U.S. and Europe, and that number is rising due to climate change, per Axios.
Pfizer and its partner company Valneva also have a Lyme disease vaccine in the works that has shown promise, with the company saying it could get approved as early as 2025. It is still good practice to wear long sleeves and use insect repellant to prevent tick bites in the first place, but "after years of relying on such preventive steps, an age of advanced drugs and vaccines could be nigh," Axios writes.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
The future of fluoridated water is up for debate
The Explainer The oral benefits are watery
By Devika Rao, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Polycystic ovary syndrome: what it is, how it's treated and why it's often misunderstood
The Explainer PCOS affects millions, but there is still no cure outside of treating symptoms separately
By Theara Coleman, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
The great departure: Texas OB-GYNs are leaving the Lone Star State
Under the radar The state is suffering an exodus of health care professionals, creating more maternity care deserts
By Theara Coleman, The Week US Published
-
UK gynaecological care crisis: why thousands of women are left in pain
The Explainer Waiting times have tripled over the past decade thanks to lack of prioritisation or funding for women's health
By Harriet Marsden, The Week UK Published